 Nuwellis

Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Nuwellis reports revenue growth and margin improvement in Q1 2024

Nuwellis' Q1 2024 performance showed revenue growth driven by consumable utilization, improved margins, and reduced operating losses. Challenges in critical care revenue persist, but expense reductions and growth opportunities in pediatrics signal a positive outlook.

Nuwellis reports revenue growth and operational improvements in Q2 2024

Nuwellis (NUWE) showed improved financial performance in Q2 2024 with revenue growth and reduced operating loss, despite challenges in the pediatric segment.
The company's strengths lie in successful product launches, financial stability, and increasing market presence, while facing challenges in pediatric revenue and R&D expenses.
Opportunities for Nuwellis include leveraging positive momentum, expanding product adoption, and capitalizing on its strong financial position for future growth.

Nuwellis reports Q3 revenue decline but operational improvements signal growth

Nuwellis showed mixed financial performance in Q3 2024 with revenue decline but operational improvements and net income.
The company faces challenges in certain product categories but benefits from growth opportunities like increased reimbursement rates.
Strategic decisions like terminating agreements and raising funds position Nuwellis for future growth and market competitiveness.
Overall, Nuwellis is navigating a dynamic market landscape with a focus on product effectiveness and financial sustainability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MINNEAPOLIS, June 05, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of patients suffering from fluid overload, today announced that Mike McCormick has been appointed to the company's Board of Directors. Mr. McCormick's vast experience includes more than 25 years of service in the medical device industry through varying leadership roles for several private and publicly traded companies. Mr. McCormick will also serve as Lead Independent Director and serve as a member of the Audit Committee and as Chair of the Nominating and Corporate Governance Committee of the Board.

Nuwellis Announces the Appointment of Mike McCormick to its Board of Directors

Nuwellis, Inc. (NASDAQ:NUWE ) Q1 2023 Earnings Conference Call May 9, 2023 9:00 AM ET Company Participants Vivian Cervantes - Investor Relations Nestor Jaramillo - President and Chief Executive Officer Lynn Blake - Chief Financial Officer John Kowalczyk - Senior Vice President of Sales & Marketing John Jefferies - Chief Medical Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Anthony Vendetti - Maxim Group Operator Good morning and welcome to the Nuwellis First Quarter 2023 Conference Call. All participants will be in a listen-only mode.

Nuwellis, Inc. (NUWE) Q1 2023 Earnings Call Transcript

MINNEAPOLIS, May 09, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the first quarter ended March 31, 2023.

Nuwellis, Inc. Announces First Quarter 2023 Financial Results

MINNEAPOLIS, March 21, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the peer-reviewed publication of an analysis of available ultrafiltration clinical trials with findings that support ultrafiltration as a safe and effective therapeutic option for acute decompensated heart failure (ADHF) patients who are resistant to diuretics or who have a history of multiple hospitalizations for fluid overload. The publication highlights the scale of clinical burden: “ADHF has the highest rate of hospital readmissions among all medical conditions and portends a significant financial burden on healthcare systems worldwide.”1

Nuwellis Announces Peer-Reviewed Publication of Clinical Trials Analysis Advocating the Use of Ultrafiltration for Heart Failure Patients Resistant to Diuretics

Nuwellis, Inc. (NASDAQ:NUWE ) Q4 2022 Earnings Conference Call February 28, 2023 8:30 AM ET Company Participants Vivian Cervantes - IR Nestor Jaramillo - President and CEO Lynn Blake - CFO Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Anthony Vendetti - Maxim Group Brooks O'Neil - Lake Street Capital Markets Operator Good morning, and welcome to the Nuwellis Fourth Quarter and Full Year 2022 Earnings Conference Call. [Operator Instructions] Please note that this event is being recorded.

Nuwellis, Inc. (NUWE) Q4 2022 Earnings Call Transcript

Q4 Revenue Up 42%; Expansion of Clinical Evidence Sets Stage for 2023 Growth Q4 Revenue Up 42%; Expansion of Clinical Evidence Sets Stage for 2023 Growth

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2022 Financial Results

MINNEAPOLIS, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that Nestor Jaramillo, President and Chief Executive Officer, and Lynn Blake, Chief Financial Officer, will participate in the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023.

Nuwellis to Present at the Oppenheimer 33rd Annual Healthcare Conference

MINNEAPOLIS, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its fourth quarter and full year 2022 financial results will be released on Tuesday, February 28, 2023. The company will host a conference call and webcast at 8:30 AM ET, during which management will discuss the company's financial results and provide a general business overview.

Nuwellis, Inc. To Announce Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023

MINNEAPOLIS, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid overload, today announced preliminary unaudited results for fourth quarter and full year 2022.

Nuwellis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue Results

Dr. Jefferies brings over two decades of cardiology and heart failure expertise to Nuwellis as the Company expands clinical evidence supporting the use of ultrafiltration for people with fluid overload Dr. Jefferies brings over two decades of cardiology and heart failure expertise to Nuwellis as the Company expands clinical evidence supporting the use of ultrafiltration for people with fluid overload

Nuwellis Appoints Dr. John Jefferies as Chief Medical Officer

MINNEAPOLIS, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that the Company held its adjourned special meeting of stockholders on January 4, 2023 at 2:00 p.m. (Central Time) (the “Special Meeting”). At the time of the Special Meeting, stockholders (i) approved the Warrant Proposal (as defined below) and (ii) authorized one or more adjournments of the meeting of stockholders to solicit additional proxies in the event there were insufficient votes to approve the Warrant Proposal.

Nuwellis, Inc. Announces Passage of Warrant Proposal

Approximately 4,000 children in the U.S. with AKI require Continuous Kidney Replacement Therapy (CKRT) Approximately 4,000 children in the U.S. with AKI require Continuous Kidney Replacement Therapy (CKRT)

SeaStar Medical and Nuwellis Enter into a U.S. License and Distribution Agreement for SeaStar Medical's Selective Cytopheretic Device (SCD) for Pediatric Acute Kidney Injury (AKI)

MINNEAPOLIS, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that on December 27, 2022, the Company received formal notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC indicating that Nuwellis has evidenced full compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The notice indicated that as a result of the closing bid price of the Company's common stock having been at least $1.00 per share for a minimum of 10 consecutive business days, the Company has regained compliance under Nasdaq Listing Rule 5550(a)(2) and advised that the matter is now closed.

Nuwellis, Inc. Announces Compliance With Nasdaq Listing Requirements

MINNEAPOLIS, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that the Company's Special Meeting of Stockholders, on December 7, 2022 at 2:00 p.m. (CST), was convened and adjourned, without any business being conducted, due to lack of the required quorum.

Nuwellis, Inc. Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

ComSovereign Holding

Faraday Future Intelligent Electric

Helbiz

Hycroft Mining Holding Corporation

Kalera PLC

OneConnect Financial Tech Co Ltd ADR

Polished.com Inc

Stryve Foods

Tricida Inc

Penny stocks to buy for under $1 but are they worth the risk? The post 10 Top Penny Stocks To Watch Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Watch Under $1 Right Now

Cosmos Holdings

Use these tips for buying penny stocks right now The post Buying Penny Stocks as 2022 Ends? 3 Tips and Tricks  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Buying Penny Stocks as 2022 Ends? 3 Tips and Tricks

Penny stocks to buy for under $1 but are they worth the risk? The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 6 To Watch Under $1 Right Now

Nuwellis, Inc. (NASDAQ:NUWE ) Q3 2022 Earnings Conference Call November 8, 2022 9:00 AM ET Company Participants Vivian Cervantes - IR Nestor Jaramillo - President & Chief Executive Officer Lynn Blake - CFO Conference Call Participants Jeff Cohen - Ladenburg Thalmann Charlie Montang - Lake Street Capital Markets Operator Good day and welcome to the Nuwellis Third Quarter 2022 Earnings Conference Call. [Operator Instructions] Please be advised today's conference is being recorded.

Nuwellis, Inc. (NUWE) Q3 2022 Earnings Call Transcript

MINNEAPOLIS, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the third quarter ended September 30, 2022.

Nuwellis, Inc. Reports Third Quarter 2022 Financial Results

MINNEAPOLIS, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE) announced today that its third quarter 2022 financial results will be released on Tuesday, November 8, 2022. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview.

Nuwellis, Inc. To Announce Third Quarter 2022 Financial Results on November 8, 2022

Lynn Blake to serve as Chief Financial Officer Lynn Blake to serve as Chief Financial Officer

Nuwellis Announces Appointment of Chief Financial Officer

MINNEAPOLIS, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) ("Nuwellis" or the "Company"), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the closing of an underwritten public offering of units with gross proceeds of approximately $11.04 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by Nuwellis.

Nuwellis Announces Closing of $11.04 Million Underwritten Public Offering Including Full Exercise of Overallotment Option

The stock price of Nuwellis (NUWE) dropped by 21.54% in the most recent trading session. This is why.

Nuwellis (NUWE) Stock: Why It Dropped 21.54%

MINNEAPOLIS, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the pricing of an underwritten public offering of units for gross proceeds of approximately $9.6 million prior to deducting underwriting discounts and commissions and offering expenses payable by Nuwellis.

Nuwellis Announces Pricing of $9.6 Million Upsized Underwritten Public Offering

Statistically Significant Reduction in CV Mortality and HF Rehospitalizations as Compared to IV Diuretics at 30 and 90 Days Statistically Significant Reduction in CV Mortality and HF Rehospitalizations as Compared to IV Diuretics at 30 and 90 Days

Nuwellis Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality at the 2022 HFSA Meeting

News for Nuwellis Stock (NUWE)